This study is looking at how a special imaging agent, 99mTc-PSMA-I&S, spreads throughout the body in men with prostate cancer. This agent is given through an IV and helps doctors see if prostate cancer has spread to the lymph nodes during surgery. You might be able to join if you are a man with prostate cancer (either new or returning), have had a 68Ga-PSMA-11 PET/CT scan showing lymph nodes are involved, and are scheduled for lymph node removal surgery. The main goal is to understand how much of the 99mTc-PSMA-I&S is found in both healthy and cancerous tissues. The study is currently unclear on its recruitment status and plans to enroll 30 participants.

Study design

This is an interventional study with 30 participants. The first 5 participants will receive two doses of 99mTc-PSMA-I&S and undergo multiple SPECT/CT scans, while subsequent participants receive one dose before surgery.

What's involved

You would receive an IV injection of 99mTc-PSMA-I&S and undergo SPECT/CT scans. If you are one of the first 5 participants, you will have 5 scans over 1-46 hours after the first dose, then a second dose before surgery.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint measures are taken at various times from 1 to 46 hours after injection, which suggests imaging will occur within this timeframe.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.